Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-585-2 | CAS number: 108-46-3
Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: No additional details available. Included due to prior inclusion in SIAR.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unknown
- Author:
- Thomas and Gisburn
- Year:
- 1 961
- Bibliographic source:
- Br. J. Dermatol. 73:378-381
Materials and methods
- Type of study / information:
- Human exposure information
- Endpoint addressed:
- not applicable
- other: Pharmacokinetic: report of excretion of resorcinol in urine
Test guideline
- Qualifier:
- no guideline available
Test material
- Reference substance name:
- Resorcinol
- EC Number:
- 203-585-2
- EC Name:
- Resorcinol
- Cas Number:
- 108-46-3
- Molecular formula:
- C6H6O2
- IUPAC Name:
- resorcinol
- Details on test material:
- 12.5% Resorcinol in a topical ointment
Constituent 1
Method
- Ethical approval:
- not specified
- Details on study design:
- One female
- Details on exposure:
- ca. 500g/week of an ointment containing 12.5 % resorcinol, for 13 years to an open leg ulcer
Results and discussion
- Results:
- In one female patient with leg ulcers treated dermally for 13 years with ca. 500g/week of an ointment containing 12.5 % resorcinol, 2.1 % of the applied dose was found in urine as glucuronide and monosulphate metabolites.
Applicant's summary and conclusion
- Conclusions:
- In one female patient with leg ulcers treated dermally for 13 years with ca. 500g/week of an ointment containing 12.5 % resorcinol, 2.1 % of the applied dose was found in urine as glucuronide and monosulphate metabolites.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
